bullish

2023 High Conviction: Revolution Medicines – Cracking The KRAS In Cancer

493 Views25 Nov 2022 01:30
Oncology-focused unicorn Revolution Medicines is our high-risk/high-reward conviction idea for 2023 as we see room for further gains among select names in the oncology biotech industry in the U.S.
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
  • Unlock all research summaries
  • Follow top, independent analysts
  • Receive personalised alerts and emails
  • Access Briefings, Analytics, and Events

Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.

Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 21-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
Rising
Andrei Zakharov
Covering IPOs, Healthcare and Technology Stocks
Information Technology & EnergyEquitiesEquity Capital MarketsThematic (Sector/Industry)
Price Chart(Sign Up to Access)
analytics-chart
x